Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Business
81 Articles Available
2
4
Can't find what you're looking for? Try our
advanced search
.
Acquisition
Stratford Pharmaceuticals, LLC Acquired by Eli Global
PR-M09-18-NI-055
Artificial Intelligence
WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
PR-M09-18-NI-054
Collaboration
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
PR-M09-18-NI-052
Collaboration
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells
PR-M09-18-NI-049
Acquisition
Portage to Acquire SalvaRx Limited
PR-M09-18-NI-042
Investment
AxiaMed Announces $12.4 Million Capital Investment Led By Health Enterprise Partners
PR-M09-18-NI-036
Strategic Collaboration
Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda
PR-M09-18-NI-035
Drug Development
The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease
PR-M09-18-NI-030
Acquisition
Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.
PR-M09-18-NI-028
Acquisition
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
PR-M09-18-NI-011
Licensing Agreement
Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt
PR-M09-18-NI-008
Neuroprotective Therapies
Accelerator Life Science Partners Launches Magnolia Neurosciences Corporation with $31 Million Series A to Develop Targeted Neuroprotective Therapies
PR-M09-18-NI-004
Generics
FDA Approves First Generic Drug Under New Pathway Aimed at Enhancing Market Competition for Sole Source Drugs
PR-M08-18-NI-108
Acquisition
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
PR-M08-18-NI-107
Agreement
NuCryo Vascular Announces Commercialization Agreement with Lokai Medical for Innovative Treatment for Peripheral Arterial Disease
PR-M08-18-NI-105
Collaboration
Trans-Hit Bio Signs an Exclusive Commercial Agreement with the Biobank of the Maricopa Integrated Health System (MIHS) to Support Industry R&D
PR-M08-18-NI-104
Collaboration
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
PR-M08-18-NI-102
Business
Perrigo to Divest Its Prescription Drug Business
PAO-M08-18-NI-015
Market Intelligence
Forces Driving Growth in the U.S. Surgical Microscopes Market
PAO-08-18-CL-001
Investment
Investing in Chinese Pharma Companies Proves Profitable
PR-M05-18-NI-023
Mergers & Acquisitions
Inside Mergers & Acquisitions
PAP-Q2-18-CL-001
Investment
Taking Middle-Market CROs and CDMOs to the Next Level
PAP-Q2-18-CL-003
Corporate Social Responsibility
Corporate Social Responsibility as a Driver for Improved Sustainability
PAP-Q2-18-CL-014
Cell and Gene Therapy
Oxford BioMedica is Making Big Moves
PAO-M03-18-NI-012
«
2
4
»
